Multi Drug Rapid Test (DTS152)

Regulatory status: For research use only, not for use in diagnostic procedures.

Write a review

Intended Use
The CD Pro Multi Drug Screening Test is a rapid, self-timed, qualitative immunoassay for the detection of drugs of abuse in urine. The cut-off concentrations for this test are Methamphetamine at 500 ng/mL, Amphetamine at 1000 ng/mL, THC metabolite (THCA) at 50 ng/mL, Cocaine metabolite (Benzoylecgonine) at 300 ng/mL and Opiates at 300 ng/mL. This assay is intended for professional use.
Store at room temperature (15-28 °C). Do not freeze. Refer to expiration date for stability.
The sensitivity of the CD Pro Multi Drug Screening Test was evaluated on clinical (urine) samples and compared with a commercially available immunoassay at the cutoff concentrations.


Have you cited DTS152 in a publication? Let us know and earn a reward for your research.

Customer Reviews

Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket


Genetic variation in the farnesoid X-receptor predicts Crohn's disease severity in female patients


Authors: Wilson, Aze; Wang, Qian; Almousa, Ahmed A.; Jansen, Laura E.; Choi, Yun-hee; Schwarz, Ute I.; Kim, Richard B.

The farnesoid X receptor (FXR) is implicated in Crohn's disease (CD) pathogenesis. It is unclear how genetic variation in FXR impacts CD severity versus genetic variation in nuclear receptors such as pregnane X receptor (PXR) and the multi-drug resistance protein 1 (MDR1, ABCB1). To evaluate FXR-1G>T as a genomic biomarker of severity in CD and propose a plausible molecular mechanism. A retrospective study (n=542) was conducted in a Canadian cohort of CD patients. Genotypic analysis (FXR-1G>T, MDR1 3435C>T and PXR -25385C>T) as well as determination of the FXR downstream product, fibroblast growth factor (FGF) 19 was performed. Primary outcomes included risk and time to first CD-related surgery. The effect of estrogen on wild type and variant FXR activity was assessed in HepG2 cells. The FXR-1GT genotype was associated with the risk of (odds ratio, OR=3.34, 95% CI=1.58-7.05, p=0.002) and earlier progression to surgery (hazard ratio, HR=3.00, 95% CI=1.86-4.83, p<0.0001) in CD. Female carriers of the FXR-1GT genotype had the greatest risk of surgery (OR=14.87 95% CI=4.22-52.38, p<0.0001) and early progression to surgery (HR=6.28, 95% CI=3.62-10.90, p<0.0001). Women carriers of FXR-1GT polymorphism had a three-fold lower FGF19 plasma concentration versus women with FXR-1GG genotype (p<0.0001). In HepG2 cells cotransfected with estrogen receptor (ER) and FXR, presence of estradiol further attenuated variant FXR activity. MDR1 and PXR genotypes were not associated with surgical risk. Unlike MDR1 and PXR, FXR-1GT genetic variation is associated with earlier and more frequent surgery in women with CD. This may be through ER-mediated attenuation of FXR activation.

Diagnosis and treatment of gonorrhoea: 2019 Belgian National guideline for primary care


Authors: Jespers, Vicky; Stordeur, Sabine; Vanden Berghe, Wim; Mokrane, Saphia; Libois, Agnes; Kenyon, Chris; Jones, Clare; Dekker, Nicole; De Canniere, Anne-Sophie; De Baetselier, Irith; Crucitti, Tania

Objectives Gonorrhoea continues to be a public health concern in Belgium with pharyngeal and rectal infections increasing in persons with high-risk sexual behaviour. Belgian health care practitioners rely on international guidance when managing gonorrhoea resulting in non-adapted suboptimal care for the Belgian patient. This guideline will rectify this situation. Methods This guideline was developed following an evidence-based approach and involving a guideline development group (GDG). Research questions were prioritised by the GDG and researchers conducted a systematic review of the evidence that was assessed using GRADE approach. Results The guideline offers recommendations for gonorrhoea diagnosis, treatment and management for primary care professionals in Belgium and applies a risk group approach. This approach aims for improved identification of at-risk persons and targeted testing of at-risk groups; it includes behavioural questioning when deciding on diagnostic sampling and provides clear advice on treatment. The guideline defines when to add surveillance testing for antibiotic resistance, and what consists of good follow-up. Results A concerted application of this guideline by all stakeholders in Belgium may result in improving the diagnosis of infections and eventually addressing the emerging multi-drug resistance.

Online Inquiry

Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:
Verification code
Click image to refresh the verification code.

Online Inquiry

  Interested in larger quantities ? request a quote!
  Protocol may be improved. Please feel free to contact us to obtain the latest version.!

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

OUR PROMISE TO YOU Guaranteed product quality expert customer support

Inquiry Basket